XM không cung cấp dịch vụ cho cư dân của Mỹ.
I
I

Incyte


Tin tức

S&P 500 top and bottom performing stocks at about 03:30 p.m. EDT

BUZZ - S&P 500 top and bottom performing stocks at about 03:30 p.m. EDT S&P 500 .SPX Top Performers Percent Change Bath & Body Works Inc BBWI.N +6.5% Intel Corp INTC.OQ +6.4% Oracle Corp ORCL.N +4.9% Incyte Corp INCY.OQ +4.3% Vistra Corp VST.N +4.2% Bottom Performers Percent Change Qorvo Inc QRVO.OQ -6.9% Skyworks Solutions Inc SWKS.OQ -5.9% Micron
I
I
M
Q
S
U

U.S. Avalonbay Communities, Elf Beauty, Evercore

U.S. RESEARCH ROUNDUP-Avalonbay Communities, Elf Beauty, Evercore Sept 16 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Avalonbay Communities, Elf Beauty and Evercore on Monday. HIGHLIGHTS * Avalonbay Communities Inc AVB.N : JP Morgan raises target price to $247 from $212 * Colgate-Palmolive Co CL.N : Wells Fargo cuts to underweight from equal-weight * Elf Beauty Inc ELF.N : Piper Sandler cuts target price to $162
C
G
G
I
C
E
E
C

Incyte's blood cancer drug succeeds late-stage trial

Incyte's blood cancer drug succeeds late-stage trial Aug 15 (Reuters) - Incyte INCY.O said on Thursday its drug met the main goal in a late-stage trial evaluating it in patients with a form of blood cancer. The company said its drug Monjuvi, combined with Bristol Myers Squibb's BMY.N drug, Revlimid, and Biogen's BIIB.O Rituxan achieved progression free survival in patients with follicular lymphoma (FL), when compared to Rituxan and Revlimid alone.
B
G
I
N

Incyte Announces Topline Results From Study Of Tafasitamab (Monjuvi®)

BRIEF-Incyte Announces Topline Results From Study Of Tafasitamab (Monjuvi®) Aug 15 (Reuters) - Incyte Corp INCY.O : INCYTE ANNOUNCES POSITIVE TOPLINE RESULTS FROM PIVOTAL STUDY OF TAFASITAMAB (MONJUVI®) IN RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA INCYTE: PHASE 3 INMIND TRIAL MET ITS PRIMARY ENDPOINT INCYTE:EXPECTS TO FILE SUPPLEMENTAL BIOLOGICS
I

Syndax rises as FDA approves company's treatment for chronic graft-versus-host disease

BUZZ-Syndax rises as FDA approves company's treatment for chronic graft-versus-host disease ** Shares of Syndax Pharmaceuticals SNDX.O rise 4% to $20.37 in afternoon trade ** The U.S. FDA, late on Wednesday, approved Syndax and partner Incyte's INCY.O drug Niktimvo for patients with chronic graft-versus-host disease (GvHD) ** GvHD is a potentially
I
S

U.S. Allstate, bluebird bio , Vicinity Motor

U.S. RESEARCH ROUNDUP-Allstate, bluebird bio , Vicinity Motor Aug 15 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Allstate, bluebird bio and Vicinity Motor, on Thursday. HIGHLIGHTS * Allstate Corp ALL.N : CFRA cuts to hold from buy * Autodesk Inc ADSK.O : Baird raises target price to $295 from $289 * bluebird bio Inc BLUE.O : JP Morgan cuts to neutral from overweight * Provident Financial Services Inc PFS.N : KBW
A
A
C
G
I
K
D
A

Incyte, Syndax Get FDA Approval For Niktimvo (axatilimab-csfr)

BRIEF-Incyte, Syndax Get FDA Approval For Niktimvo (axatilimab-csfr) Aug 14 (Reuters) - Incyte Corp INCY.O : INCYTE AND SYNDAX ANNOUNCE U.S. FDA APPROVAL OF NIKTIMVO™ (AXATILIMAB-CSFR) FOR THE TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE (GVHD) Source text for Eikon: ID:nBw712pWHa Further company coverage: INCY.O
I

FDA approves Incyte's treatment for chronic graft-versus-host disease

UPDATE 2-FDA approves Incyte's treatment for chronic graft-versus-host disease Rewrites throughout, adds analyst comment in paragraph 9 By Christy Santhosh and Sruthi Narasimha Chari Aug 14 (Reuters) - The U.S. Food and Drug Administration on Wednesday approved Incyte's INCY.O treatment for chronic graft-versus-host disease (GvHD), a potentially fatal complication that could occur after a stem cell transplant.
I
S

U.S. Booking Holdings, Doordash, Vertex Pharmaceuticals (Aug. 5)

CORRECTED-U.S. RESEARCH ROUNDUP-Booking Holdings, Doordash, Vertex Pharmaceuticals (Aug. 5) Corrects U.S. research roundup dated Aug. 5 to remove dated research actions from headline and tables, the errors appeared in previous versions also Aug 5 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies including Booking Holdings, Doordash and Vertex Pharmaceuticals, on Monday.
A
A
B
I
M
P
A
A
E
A
E
I
A
A
A
A
F
G
H
L
L

Incyte Corp reports results for the quarter ended in June - Earnings Summary

Incyte Corp reports results for the quarter ended in June - Earnings Summary Incyte Corp INCY.OQ reported a quarterly adjusted loss of $1.82​​ per share for the quarter ended in June, lower than the same quarter last year, when the company reported EPS of 99 cents. The mean expectation of twenty two analysts for the quarter was for a loss of $1.55 per share.
I

Incyte raises lower end of 2024 sales forecast for blood disorder drug Jakafi

Incyte raises lower end of 2024 sales forecast for blood disorder drug Jakafi July 30 (Reuters) - Incyte Corp INCY.O on Tuesday raised the lower end of the annual sales forecast range for its blood disorder drug Jakafi, on the back of strong demand for the treatment, and also reported better-than-expected quarterly revenue of a newer drug. Shares of the company rose 3.4% before the bell.
I
N

Incyte Q2 Adjusted 1.82

BRIEF-Incyte Q2 Adjusted EPS USD -1.82 Jul 30 (Reuters) - Incyte Q2 EPS USD -2.04. Q2 adjusted operating income USD -378.801 million Q2 operating income USD -478.13 million Q2 revenue USD 1,043.759 million
I

Microsoft and job openings to hit pre-Fed vigil

MORNING BID AMERICAS-Microsoft and job openings to hit pre-Fed vigil A look at the day ahead in U.S. and global markets from Mike Dolan To the extent that worries about pricey tech stocks and rising AI capex spending were partly behind last week's market shakeout, Microsoft's quarterly update should prove a key moment later on Tuesday, just as the Federal Reserve's latest policy meeting gets under way.
A
A
E
G
I
M
M
N
P
S
U
A
G
J
U
U
U
F
E
E
S
A
H
L

Incyte Corp <INCY.OQ> expected to post earnings of $1.11 a share - Earnings Preview

Incyte Corp expected to post earnings of $1.11 a share - Earnings Preview Incyte Corp INCY.OQ INCY.O is expected to show a rise in quarterly revenue when it reports results on July 30 for the period ending June 30 2024 The Wilmington Delaware-based company is expected to report a 6.4% increase in revenue to $1.015 billion from $954.61 million a year ago, according to the mean estimate from 18 analysts, based on LSEG data.
I

U.S. Alexander & Baldwin, Instructure Holdings, RPM International

U.S. RESEARCH ROUNDUP-Alexander & Baldwin, Instructure Holdings, RPM International July 26 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Alexander & Baldwin, Instructure Holdings and RPM International, on Friday. HIGHLIGHTS * Alexander & Baldwin Inc (Hawaii) ALEX.N : Piper Sandler raises to overweight from neutral * First Financial Northwest Inc FFNW.O : Piper Sandler cuts to neutral from overweight * Instructure H
C
D
H
I
A
D
E
A
A
C
E
G

U.S. BlackRock, Goldman Sachs, Netflix

U.S. RESEARCH ROUNDUP-BlackRock, Goldman Sachs, Netflix July 17 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including BlackRock, Goldman Sachs and Netflix, on Tuesday. HIGHLIGHTS * Ameriprise Financial Inc AMP.N : RBC raises target price to $487 from $480 * BlackRock BLK.N : JP Morgan raises target price to $774 from $756 * Goldman Sachs GS.N : HSBC raises target price to $527 from $493 * Moody's Corp MCO.N : JP Morgan rai
A
A
B
C
G
I
N
A
D
G
S
W
A
P

U.S. STOCKS Helios Technologies, Indivior, Principal Financial

BUZZ-U.S. STOCKS ON THE MOVE-Helios Technologies, Indivior, Principal Financial Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 The S&P 500 and the Nasdaq hovered at record highs on Tuesday, propelled by gains in Nvidia and other megacaps, as U.S.
I
I
N
P
T
C
U
U
S

U.S. STOCKS Tesla, Archer Aviation, Novo Nordisk

BUZZ-U.S. STOCKS ON THE MOVE-Tesla, Archer Aviation, Novo Nordisk Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 The Nasdaq and the S&P 500 edged up on Tuesday, boosted by gains in Tesla and megacap stocks, while the Dow was flat with investors assessing Federal Reserve Chairman Jerome Powell's comments on the need for more evidence before cutting rates.
I
P
P
P
P
T
L
O
W
U
U
U

U.S. STOCKS Tesla, Pure Storage, Rivian

BUZZ-U.S. STOCKS ON THE MOVE-Tesla, Pure Storage, Rivian Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street indexes traded lower on Tuesday after Federal Reserve Chairman Jerome Powell said more evidence was needed before cutting interest rates, while gains in Tesla shares kept losses in check.
I
P
P
T
L
O
W
U
U
U

U.S. STOCKS PayPal, Paramount Global, Novo Nordisk

BUZZ-U.S. STOCKS ON THE MOVE-PayPal, Paramount Global, Novo Nordisk Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street was on track for a lower open on Tuesday as megacap stocks retreated after a strong session, with additional caution creeping in ahead of jobs opening data and comments from Federal Reserve Chairman Jerome Powell later in the day.
I
P
T
U
R



Các điều kiện

Các tài sản phổ thông

Khước từ trách nhiệm: các tổ chức thuộc XM Group chỉ cung cấp dịch vụ khớp lệnh và truy cập Trang Giao dịch trực tuyến của chúng tôi, cho phép xem và/hoặc sử dụng nội dung có trên trang này hoặc thông qua trang này, mà hoàn toàn không có mục đích thay đổi hoặc mở rộng. Việc truy cập và sử dụng như trên luôn phụ thuộc vào: (i) Các Điều kiện và Điều khoản; (ii) Các Thông báo Rủi ro; và (iii) Khước từ trách nhiệm toàn bộ. Các nội dung như vậy sẽ chỉ được cung cấp dưới dạng thông tin chung. Đặc biệt, xin lưu ý rằng các thông tin trên Trang Giao dịch trực tuyến của chúng tôi không phải là sự xúi giục, mời chào để tham gia bất cứ giao dịch nào trên các thị trường tài chính. Giao dịch các thị trường tài chính có rủi ro cao đối với vốn đầu tư của bạn.

Tất cả các tài liệu trên Trang Giao dịch trực tuyến của chúng tôi chỉ nhằm các mục đích đào tạo/cung cấp thông tin và không bao gồm - và không được coi là bao gồm - các tư vấn tài chính, đầu tư, thuế, hoặc giao dịch, hoặc là một dữ liệu về giá giao dịch của chúng tôi, hoặc là một lời chào mời, hoặc là một sự xúi giục giao dịch các sản phẩm tài chính hoặc các chương trình khuyến mãi tài chính không tự nguyện.

Tất cả nội dung của bên thứ ba, cũng như nội dung của XM như các ý kiến, tin tức, nghiên cứu, phân tích, giá cả, các thông tin khác hoặc các đường dẫn đến trang web của các bên thứ ba có trên trang web này được cung cấp với dạng "nguyên trạng", là các bình luận chung về thị trường và không phải là các tư vấn đầu tư. Với việc các nội dung đều được xây dựng với mục đích nghiên cứu đầu tư, bạn cần lưu ý và hiểu rằng các nội dung này không nhằm mục đích và không được biên soạn để tuân thủ các yêu cầu pháp lý đối với việc quảng bá nghiên cứu đầu tư này và vì vậy, được coi như là một tài liệu tiếp thị. Hãy chắc chắn rằng bạn đã đọc và hiểu Thông báo về Nghiên cứu Đầu tư không độc lập và Cảnh báo Rủi ro tại đây liên quan đến các thông tin ở trên.

Cảnh báo rủi ro: Vốn của bạn bị rủi ro. Các sản phẩm có đòn bẩy có thể không phù hợp với tất cả mọi người. Hãy xem kỹ Thông báo rủi ro của chúng tôi.